DaVita Inc. (NYSE:DVA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of DaVita Inc. (NYSE:DVA) have been assigned a consensus recommendation of “Hold” from the eight analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $199.1667.

Several equities research analysts have commented on DVA shares. UBS Group boosted their target price on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research note on Monday. Truist Financial boosted their target price on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research note on Friday, May 8th. Deutsche Bank Aktiengesellschaft upgraded DaVita from a “hold” rating to a “buy” rating and boosted their target price for the company from $126.00 to $220.00 in a research note on Wednesday, May 6th. Finally, TD Cowen boosted their target price on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday, May 11th.

Insider Activity

In other news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. This represents a 27.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On DaVita

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Cozad Asset Management Inc. acquired a new position in shares of DaVita during the 1st quarter worth about $212,000. Western Wealth Management LLC bought a new position in DaVita during the first quarter worth about $60,000. Edgestream Partners L.P. bought a new position in DaVita during the first quarter worth about $398,000. Kentucky Retirement Systems bought a new position in DaVita during the first quarter worth about $2,240,000. Finally, Janus Henderson Group PLC grew its holdings in DaVita by 96.2% during the first quarter. Janus Henderson Group PLC now owns 37,188 shares of the company’s stock worth $5,716,000 after purchasing an additional 18,237 shares during the period. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE DVA opened at $198.19 on Wednesday. The stock has a market capitalization of $12.72 billion, a price-to-earnings ratio of 18.39, a PEG ratio of 0.63 and a beta of 0.91. The stock’s 50 day moving average price is $173.05 and its two-hundred day moving average price is $144.47. DaVita has a 52 week low of $101.00 and a 52 week high of $202.69.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts forecast that DaVita will post 15.07 EPS for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.